The global sales of endoscopic retrograde cholangiopancreatography (ERCP) devices are estimated to be worth USD 1,628.6 million in 2024 and are anticipated to reach a value of USD 3,000.2 million by 2034. Sales are projected to rise at a CAGR of 6.3% over the forecast period between 2024 and 2034. The revenue generated by endoscopic retrograde cholangiopancreatography (ERCP) devices in 2023 was USD 1,532.1 million.
The ERCP device market is rising rapidly across the world because of the rising incidences of gastrointestinal and pancreatic biliary disorders. ERCP is a hybrid procedure of fluoroscopy and endoscopy to diagnose and treat gallstones, bile duct obstructions, and pancreatic cancers.
ERCP devices are now crucial because they link imaging to a therapeutic procedure, enhancing modern gastroenterology practice. The increasing global burden of cancers and gallstones, in combination with more prevalent low-invasive approaches, are the mainspring driving growth in the market.
Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 1,532.1 million |
| Estimated Size, 2024 | USD 1,628.6 million |
| Projected Size, 2034 | USD 3,000.2 million |
| Value-based CAGR (2024 to 2034) | 6.3% |
A considerable amount of funds is being invested in hospitals and healthcare institutions in relation to improved endoscopic capabilities, particularly increasing ERCP capabilities.
The demand for these endoscopic devices is anticipated to grow as preference continues to change towards minimally invasive surgical procedures instead of traditional open surgery, allowing for less recovery time and decreased complication risk. Increased government spending on healthcare infrastructure in many countries will also continue to contribute to the demand for ERCP devices, as advanced surgeries are on the rise.
Substitutes such as MRCP and CT scans offer competition to the ERCP device market, as although usable for diagnostic purposes, they lack the additional therapeutic capability of an ERCP. This operational capacity allows for concurrent diagnosis and treatment and plays a significant role in securing the procedural position of ERCP in the healthcare setting, while competing with non-invasive imaging alternatives.
The market had a temporary decline as a result of the COVID-19 pandemic, with non-emergency procedures such as ERCP more often postponed and hospitals engaged in restricted patient visits to reduce the transmission of the virus.
A report documented that almost half of the endoscopy procedures were canceled across the hospitals in Germany or around the globe, so while thus causing a lesser demand for ERCP devices. Significant caution was also taken on generating aerosols in interim endoscopy procedures, especially at an indirect period during the pandemic, thus diversifying caution on procedures such as ERCP.
The ERCP device market is predicted to recover during the transition among hospitals returning patients to pre-pandemic levels. Research in the diagnosis of GI Cancers is gaining more production demands, financial investment in medical technology is ongoing, and with the trend of enhancing minimally invasive procedures evident, the demand for ERCP devices will substantially grow over the next few years.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The table below compares the compound annual growth rate (CAGR) for the global endoscopic retrograde cholangiopancreatography (ERCP) Devices market from 2023 to 2024 during the first half of the year.
This overview highlights key changes and trends in revenue growth, offering valuable insights into market dynamics. H1 covers January to June, while H2 spans July to December. In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 7.6%, followed by a slightly lower growth rate of 7.0% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 7.6% (2023 to 2033) |
| H2 | 7.0% (2023 to 2033) |
| H1 | 6.3% (2024 to 2034) |
| H2 | 6.0% (2024 to 2034) |
Moving into the subsequent period, from H1 2024 to H2 2034, the CAGR is projected to decrease slightly to 6.3% in the first half and projected to lower at 6.0% in the second half. In the first half (H1) the market witnessed a decrease of 130 BPS while in the second half (H2), the market witnessed a decrease of 100 BPS.
Increasing Prevalence of Cancer Drives Demand for Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices
Rising incidence of cancer and gastrointestinal diseases is the primarily driver of the global ERCP devices market. Among the pancreatic, liver, and biliary tract, demands the use of precise diagnostic and therapeutic equipment such as ERCP devices.
ERCP procedure is one-stop as both acute target and long-term management of cancer can be performed in a single go; this provides therapies convenience for patients and practitioners. Rising demand for minimally invasive surgeries is one of the growth determinants as it reduces the recovery time and risk of complication and related health impacts favoring the patient and practitioner requirements.
Surging incidence of chronic biliary tract and other gastrointestinal diseases-pancreatitis, inflammatory bowel diseases, and gastroesophageal reflux diseases (GERD), and increased geriatric population will drive the consumption of ERCP devices. The introduction of advanced and user-friendly equipment, shifting economic powers, and increasing government funding primarily in emerging economies are also expected to foster the market growth.
Expansion in Emerging Markets Present Significant Growth Opportunities for the ERCP Devices Market
The market for ERCP devices is experiencing ample growth opportunities, especially in emerging economies such as Brazil, Russia, India, China, and South Africa (BRICS). These economies have shown signs of rapid economic growth and constituted nearly one-third of global healthcare expenditure in 2021 (World Economic Forum).
With China and India making up over half of the world's population, this can lead to a sizeable patient population and greater demand for advanced diagnostic and therapeutic products, all of which ERCP devices are capable of addressing.
The rapidly improving healthcare infrastructure, the growing number of cancers, and the increase in medical tourism within these economies encourage global market participants to consider expanding their market. As an example, companies have established relatively sizeable production and R&D facilities within Latin America, Asia Pacific, and the Middle East.
Increasing Procedural Efficiency and Preventative Measures Drive ERCP Market Trends
Trends in the ERCP devices market focus on procedures that are more efficient and prophylactic measures for complications. According to the journal Gut and Liver, 41% of doctors perform between 5 to 10 ERCP procedures a week.
Another 30% handle between 11 and 20 cases a week, indicating a consistent volume of procedures being performed and the demand for ERCP procedures due to the increase in gastrointestinal and pancreatic biliary disorders that are highly prevalent in the community.
An emerging trend is the development of specialized ERCP teams and anecdotal reports suggest that over 60% of doctors work with an advanced practice of ERCP. These specialty teams reflect the best practice focused on improving efficiency and safety while performing ERCPs. The use of dedicated fluoroscopy rooms in 68% of endoscopy or radiology units reflects investments into infrastructure and space with the purpose of improvements to efficiency and turnover in ERCP procedures.
Prophylaxis for post-ERCP pancreatitis is drawing a lot of attention as a common and serious complication. Most doctors reported that they utilize a combination of intravenous hydration, pancreatic stents, and protease inhibitors as individual arrangements, illustrating a growing standard of care to address risk management with post-ERCP pancreatitis.
Balanced propofol sedation is also becoming a more popular sedation method, with 50% of doctors stating they are utilizing this sedation modality for more efficient and safer procedural sedation.
These trends highlight the commitment to improved safety, efficiency, and outcomes of procedures, which continues to grow the market for ERCP related devices and associated equipment.
High Costs and Procedure Risks Restrict the Growth of the ERCP Devices Market
ERCP procedures are expensive due to advanced and high-quality equipment and require highly demanding human health services skills. Such costs make the procedure inaccessible, especially in low-spending regions and among small-scale healthcare providers, limiting market growth potential. Furthermore, ERCP procedures are prohibitively expensive for many patients in underfunded healthcare systems, which lowers demand for ERCP devices.
Additionally, there are risks and side effects related to ERCP procedures, which can stand as very significant barriers to the wider acceptance of the ERCP device. For instance, post-ERCP pancreatitis is one of the more common complications.
It can be as mild as severe as life threatening in some supposed cases. This concern regarding risks often deters doctors and patients from choosing ERCP for various other reasons, even though alternative procedures are in place- a case in point being MRCP.
In addition, the very complexity that crops up regarding the procedure makes accessibility rather difficult for small-scale hospitals or clinics to implement, especially among those in areas that are either underdeveloped or rural. These factors work together to keep the body in check with major barriers to the expanded adoption of ERCP devices, and thus restrain market growth overall.
Principal Consultant
The global endoscopic retrograde cholangiopancreatography (ERCP) devices industry recorded a CAGR of 5.1% during the historical period between 2019 and 2023. The growth of Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices diagnostics industry was positive as it reached a value of USD 3,000.2 million in 2034 from USD 1,628.6 million in 2024.
Throughout the previous decade, the endoscopic retrograde cholangiopancreatography (ERCP) devices market has experienced substantial growth as a result of several key factors. The treatment of pancreaticobiliary diseases (i.e., gallstones and other cancers) increased the demand for ERCP devices to complete these diagnostic and therapeutic interventions.
It was recommended that ERCP to facilitate the management of these disorders would be safe and effective, thus increasing treatment use. Ongoing advancements in endoscope technology were also responsible for moving ERCP toward being one of the primary interventions for adult patients, particularly if they were injured and required further diagnostic procedures before invasive surgical interventions could commence.
There has been growing attention placed on minimally invasive interventions, and ERCP is commonly viewed as providing excellent diagnosis and timely therapeutic intervention. Medical patients, along with their physicians, often prefer treatment using endoscopes, noting the quicker recovery period after ERCP and hospital stay.
To improve outcome efficiency ERCP teams, made up of physicians and skillful personnel for the procedures, have become relatively common and are able to facilitate improved safety and efficiency for ERCP procedures. It stands to reason then that the ERCP keeps its upward trajectory from the growth in the previous decade and some trends will encourage future growth.
Current trends in further assessment of advanced artificial intelligence and imaging technologies will be utilized in ERCP procedures. These trends have been noted to enhance the accuracy of diagnosis and procedural interventions. With the increased focus on acceptable preventive healthcare, there may be an increased focus on ERCP for early diagnosis and treatment of gastrointestinal disorders to prevent disease escalation.
Tier 1 companies are the major companies as they hold a 36.2% share worldwide. To generate superior ERCP devices, companies are devoting a substantial portion of their resources to research and development of new technologies, making competition in this sector fierce.
To stay competitive in the market, they are focused on market expansions. Some of the tier 1 level companies are Olympus Corporation, Boston Scientific Corporation, and CONMED Corporation are prominent players in the market.
Tier 2 companies are relatively smaller as compared with tier 1 players. The tier 2 companies hold a share of 24.4% worldwide. To remain competitive, tier 2 companies are also creating and pursuing targeted strategies in particular niche markets as product extensions.
These categories are specified and align with higher levels of competition. To increase their competitiveness against larger businesses, they have formed strategic alliances and are all improving regional distribution inside the regional networks. Key Companies under this category include Merit Medical Systems, TeleMed Systems, Inc., and Fujifilm Holdings Corporation, and others
Compared to Tiers 1 and 2, Tier 3 companies offer endoscopic retrograde cholangiopancreatography (ERCP) devices, but with smaller revenue spouts and less influence. These companies mostly operate in one or two countries and have a limited customer base. Tier 3 companies, although, smaller are essential for the market. The companies such as Cook Medical, Inc, Hobbs Medical, and other falls under this category.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The section below covers the industry analysis for the endoscopic retrograde cholangiopancreatography (ERCP) devices market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Asia Pacific, Europe, and others, is provided.
The United States is anticipated to remain at the forefront in North America, with a CAGR of 2.1% through 2034. In Asia Pacific, India is projected to witness the highest CAGR in the market of 7.1% by 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| United States | 2.0% |
| Germany | 2.2% |
| India | 7.1% |
| China | 6.3% |
| South Korea | 5.0% |
The United States dominates the global market with high share in 2023. The United States is expected to exhibit a CAGR of 2.0% throughout the forecast period (2024 to 2034).
The increase incidence of primary liver cancer and intrahepatic bile duct cancer in the United States is the key factor bolstering the ERCP device market in the United States. In 2024, the American Cancer Society estimates 41,630 new cases of these tumours, with 29,840 deaths expected. The remarkable increase has heightened the demand for more sophisticated diagnostic and therapeutic approaches.
By removing obstructions, performing a biopsy, and stenting, ERCP is primarily used in the diagnosis and treatment of malignancies of the liver and bile duct. Therefore, as the number of such cases increase, so also does the need for such precision-based, minimally invasive methods that would make ERCP an essential tool in any medical situation.
With this, there has been great demand for high-quality ERCP devices in the market, thereby contributing to the growth of the segment.
In 2023, Germany held a dominant revenue in the Western Europe market and is expected to grow with a CAGR of 2.2%.
In Germany, the aging population and the high number of biliary and pancreatic diseases drive the growth of the ERCP devices market. With increasing age, disorders such as gallstones, bile duct obstruction, and pancreatic cancer are also increasing, hence the necessity for ERCP as a means of diagnosing and treating.
The advanced healthcare infrastructure, favorable healthcare reimbursement policies, and availability of skilled gastroenterologists in Germany also act as further stimulants to market growth.
Moreover, an increase in the acceptance of minimally invasive procedures is driving the uptake of ERCP, given the management of complex situations includes fewer complications than with traditional surgery. The government's push for upgrading healthcare services, especially in gastroenterology, is further fuelling the demand for ERCP devices.
China occupies a leading value share in East Asia market in 2023 and is expected to grow with a CAGR of 6.3% during the forecasted period.
In China, the high-growth market for ERCP devices is being propelled by an increasing awareness of GI disorders and the burgeoning prevalence of gallstones, cholangitis, and pancreatic cancer.
Urbanization at a high speed coupled with changing food habits has contributed to the rising of these diseases among the population. Apart from that, urbanization at a rapid pace has led to the involvement of healthcare services, along with the development of better endoscopic technologies.
The modernization of healthcare infrastructure by state initiatives and the boost of medical tourism continue to provide a boost to the ERCP market. The growth in China is further propelled by the increasing acceptance of minimally invasive procedures in major hospitals and further need for better treatment options.
Growing cases of liver and pancreatic tumors, in particular, linked with lifestyle factors, such as smoking and alcohol consumption, are raising the demand for ERCP in China.
The section contains information about the leading segments in the industry. Based on disease indication, the GI cancer is expected to account 19.7% of the global share in 2024.
| Disease Indication | GI Cancer |
|---|---|
| Value Share (2024) | 19.7% |
By indication, GI cancer is expected to hold a share of 19.7% in 2024. The cancers of the gastrointestinal tract, namely, the pancreas, bile ducts, stomach, and liver respectively, keep suggesting a humungous demand for ERCP devices.
Old-age population, unhealthy food habits with next-in-line medical care coming with a general gradient of fat, and continued high consumption of tobacco, and alcohol among adults are the snippets of increased GI cancer cases.
ERCP is now an important method of treating various disorders via single-procedure imaging and therapy like manual removal of bile duct obstruction, which is very common in patients with pancreatic and bile duct cancer.
Continuing palliative care management of patients with jaundice due to obstruction and severe pain management support provides increasing ERCP use in these patients, with such cancer accounting for the largest market share for the procedure.
| By Product | Stent |
|---|---|
| Value Share (2024) | 13.7% |
Stents will account for 13.7% by product segment in 2024, and exhibit the highest CAGR in the forecast period.
Stents are a key aspect of ERCP procedures and the leading product type segment due to their widespread use in the management of obstructions in the bile duct and pancreatic duct. Urband underwritten by various conditions such as cancer, gallstones, and strictures, obstructions can cause pain or nausea.
These devices act as an effective tool for restoring the normal flow of bile or pancreatic juice in cases of obstruction. Compared to open surgery, stenting is more minimally invasive, thus coming off as the preferred option for both operators and patients.
Thus, the increase in demand for stents is attributable to the growing incidences of pancreatic and cancer-induced bile duct obstructions with application for temporary relief.
Stents are available in a variety of forms, including plastic and metal, with self-expanding metal stents (SEMS) gaining acceptance for their longevity and efficacy. Additionally, the rising use of ERCP for both therapeutic and palliative care purposes contributes to the growing demand for stents in the market.
In the ERCP market, the key manufacturers are implementing several strategic measures to stay ahead of their competitors. They are heavily investing their resources in the research and development of better materials and designs that enhance the safety and effectiveness of the catheters. New product development is also facilitated by forming joint ventures and acquiring smaller players.
Recent Industry Developments in endoscopic retrograde cholangiopancreatography (ERCP) devices Market
In terms of disease indication, the industry is divided into Gastroesophageal Reflux Disease, GI Cancer, Barrett's Esophagus, Bile Duct Diseases, Peptic Ulcer Disease, Crohn's Disease, Intestinal Pseudo-Obstruction and Ogilvie Syndrome and other disease indications
In terms of product, the industry is divided into sphincterotomes, lithotripter, endoscopes, accessories, stents, cannulas, forceps, snares, catheters, guiding wires, balloons, and others
In terms of end user, the industry is segregated into hospitals, specialty clinics, diagnostic laboratories, and others
Key countries of North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe and Middle East and Africa (MEA) have been covered in the report.
The global endoscopic retrograde cholangiopancreatography (ERCP) devices industry is projected to witness CAGR of 6.3% between 2024 and 2034.
The global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices industry stood at USD 1,532.1 million in 2023.
The global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices industry is anticipated to reach USD 3,000.2 million by 2034 end.
China is expected to show a CAGR of 6.3% in the assessment period.
The key players operating in the global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices industry include Olympus Corporation, Boston Scientific Corporation, CONMED Corporation, Cook Medical, Inc, Hobbs Medical, Merit Medical Systems, TeleMed Systems, Inc. and Fujifilm Holdings Corporation
Explore Healthcare Insights
View Reports
Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market
